Globally, Daiichi Sankyo currently ranks as one of the top twenty pharmaceutical companies, with sales last year exceeding $8 billion. As a company in existence for more than 100 years, Daiichi Sankyo is very well known in Japan-it is the country's second largest drug maker, ranking ahead of Astellas Pharma Inc. and Eisai Inc. whose sales are $7.5 and $4.6 billion, respectively.
"The legacy of Daiichi and Sankyo is more than a century of pharmaceutical experience in bringing important medical discoveries to market," Pieroni said. "We are continuing this tradition of solid R&D innovation and are confident that our company is well positioned as an emerging leader in cardiovascular care to excel in the challenging U.S. pharmaceutical marketplace-and in bringing more life sciences jobs to New Jersey."
Daiichi Sankyo Co., Ltd., (TSE: 4568), the U.S. organization's parent company, is traded on the Tokyo Stock Exchange.
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., (pronounced DIE - EECH -EE SANK- EE - O)
headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi
Sankyo Co., Ltd., Japan's second largest pharmaceutical company and a
global leader in pharmaceutical innovation since 1899. The company is
dedicated to the discovery, development and commercialization of innovative
medicines that improve the lives of patients throughout the wor
|SOURCE Daiichi Sankyo, Inc.|
Copyright©2007 PR Newswire.
All rights reserved